Avalo Therapeutics (AVTX)

Company Profile

cerecor inc. is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human brain. we are a delaware corporation, organized in april 2011 in partnership with various laboratories and research institutes at johns hopkins medical institute ("jhmi"). cerecor is focused on translational medicine – the accelerated transfer of technology from the academic laboratory to early human trials, with the goal of rapid commercialization. we acquire rights to early stage therapeutic technologies ("assets") from universities, finance and manage the development of these assets into drug candidates (to first major milestone or value inflection point) and then either commercialize or outlicense the asset.

Company profile

Ticker

AVTX

Exchange

NASDAQ

Website

www.cerecor.com

CEO

Michael F. Cola

Incorporated

Delaware

Location

Maryland

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Bausch Health Companies • Celgene ...

Former names

Cerecor Inc.

SEC CIK

0001534120

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Medgenics Medical (Israel) Ltd. • Aevi Genomic Medicine Europe ...

AVTX stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

8-K

Entry into a Material Definitive Agreement

13 Sep 23

8-K

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

13 Sep 23

8-K

Avalo Enters into Agreement to Divest AVTX-800 Series

Entry into a Material Definitive Agreement

14 Aug 23

8-K

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

8 Aug 23

8-K

Entry into a Material Definitive Agreement

7 Aug 23

424B5

Prospectus supplement for primary offering

3 Aug 23

Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates

3 Aug 23

Latest ownership filings

View all

Caissa Capital Management ltd.

ARMISTICE CAPITAL, LLC

28 Jun 23

Change in insider ownership

27 Jun 23

Change in insider ownership

20 Jun 23

Change in insider ownership

14 Jun 23

Christopher Ryan Sullivan

13 Jun 23

GARRY ARTHUR NEIL

13 Jun 23

Financial summary

Financial statements Chart AVTX financial data

Quarter (USD)	Jun 23	Mar 23	Dec 22	Sep 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	6.45 mm	6.45 mm	6.45 mm	6.45 mm	6.45 mm	6.45 mm
Cash burn (monthly)	3.48 mm	419.75 k	2.73 mm	1.91 mm	3.68 mm	1.61 mm
Cash used (since last report)	9.79 mm	1.18 mm	7.68 mm	5.37 mm	10.35 mm	4.53 mm
Cash remaining	-3.33 mm	5.27 mm	-1.23 mm	1.08 mm	-3.89 mm	1.93 mm
Runway (months of cash)	-1.0	12.6	-0.5	0.6	-1.1	1.2

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2023

AVTX institutional ownership history Ownership history

21.6% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	27	33	-18.2%
Opened positions	5	9	-44.4%
Closed positions	11	5	+120.0%
Increased positions	6	9	-33.3%
Reduced positions	5	7	-28.6%

13F shares	Current	Prev Q	Change
Total value	847.65 mm	15.87 bn	-94.7%
Total shares	4.37 mm	11.63 mm	-62.4%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Venrock Healthcare Capital Partners III	1.35 mm	$4.68 mm	0.0%
VR Adviser	1.25 mm	$444.00 mm	+25.0%
Armistice Capital	588.85 k	$294.00 k	-86.7%
Nantahala Capital Management	556.20 k	$197.56 mm	-31.2%
Vanguard	222.07 k	$78.88 mm	0.0%
BLK Blackrock	124.45 k	$44.20 mm	+20.7%
Geode Capital Management	80.97 k	$28.76 mm	+57.7%
Millennium Management	33.93 k	$12.05 mm	NEW
Virtu Financial	32.59 k	$12.00 k	NEW
STT State Street	25.64 k	$9.11 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
Armistice Capital	588.85 k	-3.83 mm	-86.7%
Caissa Capital Management	0.00	-1.21 mm	EXIT
Point72 Asset Management	0.00	-1.10 mm	EXIT
Great Point Partners	0.00	-474.64 k	EXIT
Alyeska Investment	0.00	-400.00 k	EXIT
Nantahala Capital Management	556.20 k	-252.64 k	-31.2%
VR Adviser	1.25 mm	+250.00 k	+25.0%
Braidwell	0.00	-247.25 k	EXIT
Maven Securities	0.00	-92.94 k	EXIT
Monashee Investment Management	0.00	-60.00 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

AVTX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
27 Jun 23	Armistice Capital	Common Stock	Sell	Dispose S	Yes	No	0.5194	937,404	486.89 k	731,458
26 Jun 23	Caissa Capital Management	Common Stock	Buy	Dispose P	No	No	0.62	182,300	113.03 k	0
26 Jun 23	Caissa Capital Management	Common Stock	Buy	Dispose P	Yes	No	0.6433	1,425,700	917.15 k	0
26 Jun 23	Armistice Capital	Common Stock	Sell	Dispose S	Yes	No	0.6125	2,746,138	1.68 mm	1,668,862
20 Jun 23	Caissa Capital Management	Common Stock	Buy	Acquire P	Yes	No	4.1444	2,000	8.29 k	1,425,700
16 Jun 23	Caissa Capital Management	Common Stock	Buy	Acquire P	Yes	No	3.9048	3,000	11.71 k	1,423,700
15 Jun 23	Caissa Capital Management	Common Stock	Buy	Acquire P	Yes	No	3.6837	3,160	11.64 k	1,420,700
14 Jun 23	Caissa Capital Management	Common Stock	Buy	Acquire P	Yes	No	3.479	6,000	20.87 k	1,417,540
13 Jun 23	Caissa Capital Management	Common Stock	Buy	Acquire P	Yes	No	3.8216	8,750	33.44 k	1,411,540
12 Jun 23	Caissa Capital Management	Common Stock	Buy	Acquire P	Yes	No	4.3352	2,149	9.32 k	1,402,790